Dr. Michael J. Haller, MD
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- Medical school
- University of Florida College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
FL license ME91175
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Florida Clinical Practice Association Inc (1,924 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 5 companies reported 28 payments worth $62,560 in total to this clinician.
| Sanofi-aventis U.S. LLC | $33,110 |
|---|---|
| Mannkind Corporation | $15,181 |
| Genzyme Corporation | $11,994 |
| Sanofi US Services Inc. | $2,258 |
| Beta Bionics, Inc. | $16.90 |
| Consulting Fee | $32,056 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $13,149 |
| Honoraria | $11,000 |
| Travel and Lodging | $5,270 |
| Food and Beverage | $1,042 |
| Education | $42.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi-aventis U.S. LLC May 1, 2025 | Consulting Fee TZIELD · Endocrine & Metabolic Diseases | $12,366 |
| Sanofi-aventis U.S. LLC May 13, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $11,124 |
| Genzyme Corporation Oct 24, 2025 | Consulting Fee | $10,429 |
| Sanofi-aventis U.S. LLC Sep 30, 2025 | Consulting Fee | $7,004 |
| Mannkind Corporation Sep 27, 2025 | Honoraria AFREZZA · DIABETES MEDICINE | $5,950 |
| Mannkind Corporation Apr 25, 2025 | Honoraria AFREZZA · DIABETES MEDICINE | $5,050 |
| Sanofi US Services Inc. Mar 28, 2025 | Consulting Fee | $2,258 |
| Mannkind Corporation Jul 10, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to CHICAGO, IL | $1,573 |
| Mannkind Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) AFREZZA · DIABETES MEDICINE | $1,275 |
| Sanofi-aventis U.S. LLC May 1, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Philadelphia, PA · in-kind | $664 |
All 23 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation Nov 13, 2025 | Education AFREZZA · DIABETES MEDICINE · in-kind | $42.50 |
| Genzyme Corporation Oct 24, 2025 | Consulting Fee | $10,429 |
| Genzyme Corporation Oct 24, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $617 |
| Genzyme Corporation Oct 24, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $579 |
| Sanofi-aventis U.S. LLC Sep 30, 2025 | Consulting Fee | $7,004 |
| Sanofi-aventis U.S. LLC Sep 30, 2025 | Travel and Lodging travel to Orlando, FL | $158 |
| Mannkind Corporation Sep 27, 2025 | Honoraria AFREZZA · DIABETES MEDICINE | $5,950 |
| Mannkind Corporation Jul 10, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to CHICAGO, IL | $1,573 |
| Mannkind Corporation Jul 10, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to CHICAGO, IL | $497 |
| Mannkind Corporation Jul 10, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to CHICAGO, IL | $131 |
| Mannkind Corporation Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty) AFREZZA · DIABETES MEDICINE | $1,275 |
| Sanofi-aventis U.S. LLC Jun 22, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Sanofi-aventis U.S. LLC Jun 22, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Sanofi-aventis U.S. LLC May 13, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $11,124 |
| Sanofi-aventis U.S. LLC May 13, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Copenhagen, Denmark | $56.05 |
| Sanofi-aventis U.S. LLC May 1, 2025 | Consulting Fee TZIELD · Endocrine & Metabolic Diseases | $12,366 |
| Sanofi-aventis U.S. LLC May 1, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Philadelphia, PA · in-kind | $664 |
| Sanofi-aventis U.S. LLC May 1, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Philadelphia, PA · in-kind | $278 |
| Sanofi-aventis U.S. LLC May 1, 2025 | Travel and Lodging TZIELD · Endocrine & Metabolic Diseases · travel to Philadelphia, PA | $54.65 |
| Mannkind Corporation Apr 25, 2025 | Honoraria AFREZZA · DIABETES MEDICINE | $5,050 |
| Mannkind Corporation Apr 25, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to CHICAGO, IL | $50.00 |
| Sanofi US Services Inc. Mar 28, 2025 | Consulting Fee | $2,258 |
| Mannkind Corporation Feb 13, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to CHICAGO, IL | $612 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $127,238 in research payments for these studies, mostly to the institutions running them.
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
Genzyme Corporation · Active, not recruiting · NCT06111586 - A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent…
Sanofi US Services Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.